Expert Interview
A Second Perspective: Discussing ImmunoGen's drug Mirvetuximab Soravtansine in treating ovarian cancer
Ticker(s): IMGNInstitution: University of Alabama
- Division Director and Professor, Division of Gynecologic Oncology, Margaret Cameron Spain Endowed Chair in Obstetrics/Gynecology, Vice Chair, Gynecology, Senior Medical Officer, UAB Cancer Service Line, at the O’Neal Comprehensive Cancer Center (UAB).
- Manages 325-400 patients with ovarian cancer.
- Research interests include vaccines for cervical neoplasia, in vivo spectroscopy for cervical neoplasia, and treatment approaches for endometrial cancer.
Roughly how many patients with ovarian cancer do you currently manage?
Added By: c_admin
At a high level was was your impression of the SORAYA trial of Mirvetuximab Soravtansine?
Can you comment on the overall development program in Folate-receptor alpha high expressor subset, in context of previous failed FORWARD I phase 3 trial (2019)?
Added By: c_adminWhere do you anticipate mirvetuximab will be used if approved?
Added By: c_adminDo you anticipate any challenges with the adoption of folate-receptor alpha testing? If so, please describe.
Added By: c_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
